CEO Statement to Shareholders
Rhea-AI Summary
OSR Holdings (NASDAQ:OSRH) CEO Peter Hwang issued a June 3, 2026 letter outlining strategy and Nasdaq compliance efforts. OSRH operates a biomedical portfolio in oncology, regenerative medicine, medical devices, and digital health. Vaximm signed a definitive licensing agreement for the VXM01 immunotherapy platform, described as one of the most significant transactions in company history. Woori IO continues development and strategic engagements, including with Samsung, on a noninvasive glucose monitoring platform. Management is reviewing capital allocation, partnerships, monetizations, and spin-offs while working with Nasdaq to address minimum bid price compliance.
AI-generated analysis. Not financial advice.
Positive
- Definitive licensing deal for Vaximm’s VXM01 immunotherapy platform, called highly significant
- Advancing Woori IO noninvasive glucose monitoring with global partners including Samsung
- Diversified biomedical portfolio across oncology, regenerative medicine, medical devices, and digital health
- Management evaluating capital allocation, partnerships, monetizations, and spin-offs to unlock asset value
Negative
- Company is in a Nasdaq minimum bid price compliance process
- Maintaining Nasdaq listing requires evaluating specific pathways to regain compliance
Market Reality Check
Peers on Argus
OSRH was down 5.15% ahead of this statement, while key biotech peers ADAP, APLM, APM, PHGE, and PHIO also traded lower (e.g., ADAP -17.57%, PHGE -11.4%), pointing to broader sector weakness alongside company-specific Nasdaq compliance commentary.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 27 | VXM01 IP acquisition | Positive | -2.2% | OSRH centralized full VXM01 IP portfolio via $30M asset purchase deal. |
| May 12 | CEO compliance update | Positive | +13.1% | CEO ruled out reverse split, highlighting execution to regain Nasdaq compliance. |
| May 05 | Analyst flash report | Positive | -10.8% | Research firm reiterated buy-emerging rating and $10 target post VXM01 deals. |
| Apr 30 | Conference presentation | Positive | +52.8% | Company presented VXM01 licensing agreement at Emerging Growth Conference. |
| Apr 29 | Global license deal | Positive | -38.2% | OSRH executed $815M global VXM01 license and $30M IP acquisition with BCME. |
Recent OSRH news has produced volatile and often divergent price reactions, with several positive licensing and asset deals followed by sell-offs.
Over the past months, OSRH has focused on the VXM01 immunotherapy platform and corporate positioning. On Apr 29, it executed an $815 million global license with BCM Europe and a $30 million IP acquisition, followed by a conference presentation on Apr 30 that saw a sharp gain. Subsequent research coverage and CEO communication produced mixed reactions, including a positive move on the May 12 CEO statement about avoiding a reverse split. The May 27 VXM01 IP consolidation drew a modest decline. Today’s statement reiterates strategy, value-creation tools, and Nasdaq compliance focus.
Market Pulse Summary
This announcement reiterates OSRH’s strategy as a biomedical holding company, highlighting oncology and noninvasive glucose monitoring assets while emphasizing long-term value creation. Management confirms Nasdaq minimum bid price compliance remains a priority but discloses no specific transactions, only that a full range of hub-and-spoke tools is under evaluation. In context of recent VXM01 licensing and IP acquisitions and ongoing proxy proposals, investors may watch for concrete monetization steps, partnership updates, and further clarity on Nasdaq listing outcomes.
Key Terms
immunotherapy medical
noninvasive glucose monitoring medical
Nasdaq regulatory
minimum bid price regulatory
spin-offs financial
Hub-and-Spoke technical
AI-generated analysis. Not financial advice.
BELLEVUE, WA / ACCESS Newswire / June 3, 2026 / Dear Fellow Shareholders,
As we move through 2026, I would like to provide an update on where OSR Holdings (NASDAQ:OSRH) stands today and how we are approaching the opportunities ahead:
Strategic Focus and Business Development
Over the past year, we have continued to strengthen our position as a biomedical holding company with a growing portfolio of innovative businesses spanning oncology, regenerative medicine, medical devices, and digital health. We are seeing increasing external validation of the technologies and platforms being developed by our subsidiaries.
Vaximm recently executed a definitive licensing agreement for the VXM01 immunotherapy platform, one of the most significant transactions in the Company's history. At Woori IO, development activities and strategic engagements involving global industry participants, including Samsung, continue to advance our noninvasive glucose monitoring platform.
Across our portfolio, we are focused on transforming scientific innovation into commercial opportunities and long-term shareholder value.
Value Creation Framework
As a holding company, our responsibility is to continually evaluate how best to unlock the value of our underlying businesses for the benefit of shareholders. Public markets have repeatedly demonstrated that significant value can be created through thoughtful capital allocation, strategic partnerships, subsidiary monetizations, spin-offs, and other corporate actions that allow investors to participate more directly in the success of underlying assets.
While we are not announcing any specific transaction at this time, I can assure shareholders that we are evaluating a full range of tools available to publicly listed Hub-and-Spoke biotech companies and are committed to pursuing opportunities that we believe will benefit our investors.
Nasdaq Compliance Update
We continue to work closely with Nasdaq, our advisors, and industry experts regarding our minimum bid price compliance process. Maintaining a Nasdaq listing remains an important objective, and we are evaluating pathways to achieve compliance while preserving and enhancing long-term shareholder value.
Our focus remains on building sustainable businesses, advancing technologies, creating partnerships, and positioning OSRH to unlock value over time.
Outlook
The next chapter of OSRH will not be defined by a compliance deadline or short-term considerations such as the next quarter or month, but by its ability to translate scientific innovation into enduring shareholder value.
We remain confident in our portfolio, our partners, and the opportunities before us, and we appreciate the continued trust and support of our shareholders as we execute our strategy.
Sincerely,
Peter Hwang
Chief Executive Officer
OSR Holdings, Inc.
About OSR Holdings, Inc.
OSR Holdings, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Holdings engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more at www.OSR-Holdings.com.
Investor Contact
OSR Holdings, Inc.
Investor Relations
ir@osr-holdings.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Nasdaq compliance, strategic transactions, commercialization initiatives, and future business developments. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. OSR Holdings undertakes no obligation to update these statements except as required by law.
SOURCE: OSR Holdings, Inc.
View the original press release on ACCESS Newswire